Outcomes following front-line chemotherapy in peripheral T-cell lymphoma: 10-year experience at The Royal Marsden and The Christie Hospital

Mary Gleeson, Clare Peckitt, David Cunningham, Adam Gibb, Eliza A. Hawkes, Morgan Back, Binnaz Yasar, Kate Foley, Rebecca Lee, Joanna Dash, Hannah Johnson, Catherine O’Hara, Andrew Wotherspoon, Ayoma Attygalle, Lia Menasce, Patrick Shenjere, Mike Potter, Mark E. Ethell, Claire Dearden, John RadfordIan Chau, Kim Linton

Research output: Contribution to journalArticleResearchpeer-review

10 Citations (Scopus)

Abstract

We evaluated the outcomes for patients with peripheral T-cell lymphoma (PTCL) undergoing front-line chemotherapy at our institutions between 2002 and 2012. One hundred and fifty-six patients were eligible, comprising PTCL not otherwise specified (NOS) (n = 50, 32.0%), angioimmunoblastic T-cell lymphoma (AITL) (n = 44, 28.2%), anaplastic large-cell lymphoma (ALCL) ALK negative (n = 23, 14.7%), ALCL ALK positive (n = 16, 10.3%), and other (n = 23, 14.7%). Most patients received CHOP (66.0%) and 13.0% received an autologous hematopoietic progenitor cell transplant (HPCT). With a median follow-up of 63.4 months, 5-year overall survival (OS) and progression-free survival (PFS) was 38.8% and 19.8% respectively. Independent risk factors for inferior OS were age >60 years, International Prognostic Index (IPI) ≥ 2 and lack of complete response to induction. When responding patients were compared by receipt of an autologous HPCT versus not, HPCT was associated with improved PFS (p =.001) and OS (p =.046) and remained significant for PFS in multivariate analysis suggesting a possible therapeutic benefit.

Original languageEnglish
Pages (from-to)1586-1595
Number of pages10
JournalLeukemia and Lymphoma
Volume59
Issue number7
DOIs
Publication statusPublished - 2018
Externally publishedYes

Keywords

  • chemotherapy
  • hematopoietic progenitor cell transplant
  • Peripheral T-cell lymphoma

Cite this